Nutrition support may prolong survival in high risk patients with gastric cancer

Share this content:

the ONA take:

According to a new study published in the journal Supportive Care in Cancer, researchers in China have found that nutrition support might be helpful to improve the prognosis of patients with stage IV gastric cancer whose Nutritional Risk Screening (NRS) score is 3 or higher.

For the study, researchers sought to evaluate whether nutrition support can extend survival of patients with advanced gastric cancer cancer.

Researchers prospectively evaluated the nutritional risk of 830 patients with gastric adenocarcinoma. Of those, 50.7% had an NRS ≥3. Then, patients with stage IV disease whose NRS was ≥3 were given nutrition support.

Results showed that NRS ≥3 was an independent adverse prognostic factor in patients with gastric cancer. Median survival was over 6 months longer in patients with an NRS <3.

In addition, among the 347 patients with an NRS ≥3 who were given nutrition support, those who were young, male, and achieved a good response to chemotherapy were more likely to shirt to NRS <3 after nutrition support.

Researchers found that median overall survival was 14.3 months for patients with the NRS shift compared with 9.6 months for those without the shift.

Many patients with GI cancer require nutritional guidance.
Nutrition support might be helpful to improve the prognosis of patients with stage IV gastric cancer.
The aim of our study is firstly to evaluate the prevalence and prognostic value of nutrition risk in gastric cancer patients and secondly to explore whether the nutrition support can prolong the survival of advanced gastric cancer patients. It contained two study periods.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs